Comparative Effectiveness of Sodium-Glucose Cotransporter 2 Inhibitors vs Sulfonylureas in Patients With Type 2 Diabetes
出版年份 2021 全文链接
标题
Comparative Effectiveness of Sodium-Glucose Cotransporter 2 Inhibitors vs Sulfonylureas in Patients With Type 2 Diabetes
作者
关键词
-
出版物
JAMA Internal Medicine
Volume 181, Issue 8, Pages 1043
出版商
American Medical Association (AMA)
发表日期
2021-06-28
DOI
10.1001/jamainternmed.2021.2488
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Overlap Weighting
- (2020) Laine E. Thomas et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Effect of Dapagliflozin on Worsening Heart Failure and Cardiovascular Death in Patients With Heart Failure With and Without Diabetes
- (2020) Mark C. Petrie et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Use of sodium-glucose co-transporter 2 inhibitors and risk of serious renal events: Scandinavian cohort study
- (2020) Björn Pasternak et al. BMJ-British Medical Journal
- TEMPORARY REMOVAL: Executive summary of the 2020 KDIGO Diabetes Management in CKD Guideline: Evidence-based advances in monitoring and treatment
- (2020) Ian H. de Boer et al. KIDNEY INTERNATIONAL
- Risk of cardiovascular events and death associated with initiation of SGLT2 inhibitors compared with DPP-4 inhibitors: an analysis from the CVD-REAL 2 multinational cohort study
- (2020) Shun Kohsaka et al. Lancet Diabetes & Endocrinology
- Comparative Effectiveness of the Sodium–Glucose Cotransporter 2 Inhibitor Empagliflozin Versus Other Antihyperglycemics on Risk of Major Adverse Kidney Events
- (2020) Yan Xie et al. DIABETES CARE
- Comparative Effectiveness of SGLT2 Inhibitors, GLP-1 Receptor Agonists, DPP-4 Inhibitors, and Sulfonylureas on Risk of Kidney Outcomes: Emulation of a Target Trial Using Health Care Databases
- (2020) Yan Xie et al. DIABETES CARE
- Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure
- (2020) Milton Packer et al. NEW ENGLAND JOURNAL OF MEDICINE
- Sodium glucose cotransporter 2 inhibitors and risk of major adverse cardiovascular events: multi-database retrospective cohort study
- (2020) Kristian B Filion et al. BMJ-British Medical Journal
- Out-of-Pocket Costs for Novel Guideline-Directed Diabetes Therapies Under Medicare Part D
- (2020) Colette DeJong et al. JAMA Internal Medicine
- Acute Kidney Injury in a National Cohort of Hospitalized US Veterans with COVID-19
- (2020) Benjamin Bowe et al. Clinical Journal of the American Society of Nephrology
- Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy
- (2019) Vlado Perkovic et al. NEW ENGLAND JOURNAL OF MEDICINE
- Estimates of the 2016 global burden of kidney disease attributable to ambient fine particulate matter air pollution
- (2019) Benjamin Bowe et al. BMJ Open
- Estimates of all cause mortality and cause specific mortality associated with proton pump inhibitors among US veterans: cohort study
- (2019) Yan Xie et al. BMJ-British Medical Journal
- 2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD
- (2019) Francesco Cosentino et al. EUROPEAN HEART JOURNAL
- Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction
- (2019) John J.V. McMurray et al. NEW ENGLAND JOURNAL OF MEDICINE
- Use of sodium glucose cotransporter 2 inhibitors and risk of major cardiovascular events and heart failure: Scandinavian register based cohort study
- (2019) Björn Pasternak et al. BMJ-British Medical Journal
- Effects of dapagliflozin on development and progression of kidney disease in patients with type 2 diabetes: an analysis from the DECLARE–TIMI 58 randomised trial
- (2019) Ofri Mosenzon et al. Lancet Diabetes & Endocrinology
- Potential Mechanisms of Sodium-Glucose Co-Transporter 2 Inhibitor-Related Cardiovascular Benefits
- (2019) Subodh Verma AMERICAN JOURNAL OF CARDIOLOGY
- 2019 Update to: Management of Hyperglycemia in Type 2 Diabetes, 2018. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)
- (2019) John B. Buse et al. DIABETES CARE
- Kidney outcomes associated with use of SGLT2 inhibitors in real-world clinical practice (CVD-REAL 3): a multinational observational cohort study
- (2019) Hiddo J L Heerspink et al. Lancet Diabetes & Endocrinology
- Unknown
- (2018) DIABETES OBESITY & METABOLISM
- SGLT-2 Inhibitors and Cardiovascular Risk
- (2018) Matthew A. Cavender et al. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- Cardiovascular Events Associated With SGLT-2 Inhibitors Versus Other Glucose-Lowering Drugs
- (2018) Mikhail Kosiborod et al. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- Higher blood urea nitrogen is associated with increased risk of incident diabetes mellitus
- (2018) Yan Xie et al. KIDNEY INTERNATIONAL
- Primary Prevention of Cardiovascular Disease with a Mediterranean Diet Supplemented with Extra-Virgin Olive Oil or Nuts
- (2018) Ramón Estruch et al. NEW ENGLAND JOURNAL OF MEDICINE
- Improved adherence adjustment in the Coronary Drug Project
- (2018) Eleanor J. Murray et al. Trials
- Management of Hyperglycemia in Type 2 Diabetes, 2018. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)
- (2018) Melanie J. Davies et al. DIABETES CARE
- Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes
- (2018) Stephen D. Wiviott et al. NEW ENGLAND JOURNAL OF MEDICINE
- Long-term kidney outcomes among users of proton pump inhibitors without intervening acute kidney injury
- (2017) Yan Xie et al. KIDNEY INTERNATIONAL
- Per-Protocol Analyses of Pragmatic Trials
- (2017) Miguel A. Hernán et al. NEW ENGLAND JOURNAL OF MEDICINE
- Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes
- (2017) Bruce Neal et al. NEW ENGLAND JOURNAL OF MEDICINE
- Risk of death among users of Proton Pump Inhibitors: a longitudinal observational cohort study of United States veterans
- (2017) Yan Xie et al. BMJ Open
- Cardiovascular mortality and morbidity in patients with type 2 diabetes following initiation of sodium-glucose co-transporter-2 inhibitors versus other glucose-lowering drugs (CVD-REAL Nordic): a multinational observational analysis
- (2017) Kåre I Birkeland et al. Lancet Diabetes & Endocrinology
- Proton Pump Inhibitors and Risk of Incident CKD and Progression to ESRD
- (2016) Y. Xie et al. JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY
- Canagliflozin Slows Progression of Renal Function Decline Independently of Glycemic Effects
- (2016) Hiddo J. L. Heerspink et al. JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY
- Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes
- (2016) Christoph Wanner et al. NEW ENGLAND JOURNAL OF MEDICINE
- Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes
- (2015) Bernard Zinman et al. NEW ENGLAND JOURNAL OF MEDICINE
- High-dimensional propensity score algorithm in comparative effectiveness research with time-varying interventions
- (2015) Romain Neugebauer et al. STATISTICS IN MEDICINE
- Use of Antidiabetic Drugs in the U.S., 2003–2012
- (2014) Christian Hampp et al. DIABETES CARE
- Beyond the intention-to-treat in comparative effectiveness research
- (2011) Miguel A Hernán et al. Clinical Trials
- Negative Controls
- (2010) Marc Lipsitch et al. EPIDEMIOLOGY
- High-dimensional Propensity Score Adjustment in Studies of Treatment Effects Using Health Care Claims Data
- (2009) Sebastian Schneeweiss et al. EPIDEMIOLOGY
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now